Diabetes Drug, Janumet, Linked to Cancer
Janumet is used to lower blood sugar in Type 2 Diabetes patients. The drug is in the class of DDP-4 inhibitors that work by slowing down patients’ metabolism of a hormone that signals the pancreas to release insulin. While Janumet successfully lowers insulin, it has unfortunate links to pancreatic diseases. Lawsuits claim that the drug makers failed to warn the public of the dangerous risk of pancreatitis and pancreatic cancer.
Janumet is a combination of metformin and sitagliptin. Sitagliptin, known as Januvia when it is prescribed alone, was found to have a connection to pancreatic cancer in a 2011 study. The results of the study found that patients taking sitagliptin had a 2.7 higher event rate of pancreatic cancer compared to those taking other diabetes drugs. Patients taking Janumet have also developed pancreatitis, a painful inflammation of the pancreas.
Lawsuits against the makers of Janumet, as well as three other diabetes drugs that contain sitagliptin, have been brought in many states across the U.S. So many cases were brought in California that a federal court streamlined the process by grouping together hundreds of cases in the Southern District of California. Consolidating cases helps with a consistent ruling, however each plaintiff maintains their own lawyer, suit and right to monetary award based on the specifics of their case.
If you or a family member has been diagnosed with pancreatic cancer after taking Janumet, you have legal options and stand to receive monetary compensation for lost wages, pain and suffering and medical expenses. Contact a personal injury attorney at Roberts & Roberts for a free, no obligation consultation.